Madrigal Pharmaceuticals Inc (FRA:YDO1)
€ 193.4 -1.45 (-0.74%) Market Cap: 4.17 Bil Enterprise Value: 3.29 Bil PE Ratio: 0 PB Ratio: 5.13 GF Score: 40/100

Madrigal Pharmaceuticals Inc at UBS Global Healthcare Virtual Conference Transcript

May 24, 2021 / 08:00PM GMT
Navin Jacob;UBS;Analyst;Paul A. Friedman
Madrigal Pharmaceuticals,

Good afternoon. Thanks for joining us again at the UBS Global Healthcare Conference. My name is Navin Jacob. I cover smid-cap biotech and large-cap pharma here at UBS. I'm excited to have with me our next session, Madrigal Pharmaceuticals. From Madrigal, we're happy to have with us Paul Friedman, Chief Executive Officer; Becky Taub, Chief Medical Officer and President of R&D; and the new CFO, Alex Howarth; and SVP and Chief Commercial Officer, Remy Sukhija.

So with that, we're going to spend about 15, maybe 20 minutes, on a small presentation just to give folks who are not as familiar with Madrigal a chance to learn about the company, after which we will spend about 25 to 30 minutes of Q&A from me to the management team. And if you do have questions, please submit them online. They will be anonymous, and I'm happy to read those out to the management team.

And without further ado, I will turn it over to Paul for some introductory remarks. Thank you, Paul.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot